Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Grade 3a Follicular Lymphoma: early-phase trial registry
4 of 11 indexed Grade 3a Follicular Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 4 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Grade 3a Follicular Lymphoma: 11 US clinical trials tracked, 4 recruiting.
Grade 3a Follicular Lymphoma is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is University of Washington, running 4 of these trials.
Enrollment posture brief
Registry condition grade-3a-follicular-lymphoma
OPEN 4 | RECR 36% | LATE 0 | EARLY 11 | RANK #1577 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (36% recruiting · 11 trials)
Grade 3a Follicular Lymphoma lists 4 open slots (36% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Grade 3a Follicular Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Grade 3a Follicular Lymphoma is recruiting below its size-band peers.
4 of 11 indexed trials (36.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Grade 3a Follicular Lymphoma research.
University of Washington accounts for 4 of 11 trials (36.4%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Grade 3a Follicular Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 11 trials that report a genuine target (sentinel values excluded). 11 of those (100%) plan for fewer than 100 participants.
-
Grade 3a Follicular Lymphoma research is mostly interventional.
11 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Emory University
NCT04883437
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
Joseph Tuscano
NCT04450173
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
University of Washington
NCT06948786
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
University of Washington
NCT06442475
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
NCT03269669
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
M.D. Anderson Cancer Center
NCT04404088
Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma
National Cancer Institute (NCI)
NCT01849263
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
David Bond, MD
NCT03015896
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
University of Washington
NCT04257578
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Beth Christian
NCT02992522
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
University of Washington
NCT05169658
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Grade 3a Follicular Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Grade 3a Follicular Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Grade 3a Follicular Lymphoma page
11 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Grade 3a Follicular Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Washington sponsors the most Grade 3a Follicular Lymphoma trials on record, review their full trial history before evaluating a specific study. See University of Washington's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Grade 3a Follicular Lymphoma condition card totals 11 registered trials; most-linked intervention Obinutuzumab; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.